Vine is a prolific venture capital fund operating in the world of psychedelics with the philosophy of reciprocity at its core.
Vine Ventures
The Vine Entrepreneur’s Reciprocity Pledge means that 50% of all gross profits at Vine will be deployed into non-profit initiatives to drive the psychedelics space forward. These initiatives include a mix of indigenous development projects, academic research, community organizations, and social awareness initiatives around mental health, especially among underserved demographics.
Some of their investments include Clerkenwell Health, Gilgamesh, Psygen and Bexson Biomedical.
Check out Vine Ventures Founder, Ryan Zurrer, on the Third Wave podcast here.
Vine’s Approach
“We look for special companies and entrepreneurs that meet relatively simple criteria:
- High-integrity teams looking towards building a better more inclusive future
- Teams that have deep technical competency in their field
- Products and services that occupy an important part of the value chain cited above and are defensible over time
- Businesses that can be scalable and touch a billion people’s lives.”
Key Staff
- Ryan Zurrer (Founder)
- Ozan Polat (Investor)
- Daniel Tarockoff (Investor)
- Zack Lawarene (Investor)
- Luis Rios (Senior Scientific Partner)
- Robbie Bent
Activities
B2B
Investor
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride (TechCrunch, 04 May 2022)A Look at the Vine Ventures/MAPS Funding Structure (The Truffle Report, 13 December 2021)
The Truffle Report take a closer look at the deal between Vine Ventures and MAPS.
Vine Ventures: Rethinking Venture Capital for a Novel Approach to Health & Wellness (Ryan Zurrer Medium, 07 March 2021)
Vine Ventures Founder, Ryan Zurrer, details some of the funds' strategies and more in this post.
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million (MAPS, 02 December 2021)
MAPS and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.
UK Set To Become Hub Of Psychedelic Research (Clerkenwell Health, 25 June 2021)
Clerkenwell Health closed its initial round of funding to launch a clinical research organisation with key hires and a partnership with Manchester University. Funding came from a mix of British angel investors and psychedelic focussed VCs including Vine Ventures.